Age-related macular degeneration: Update for primary care

American Family Physician

Volumn 61, Issue 10, 2000, Pages 3035-3042

  Fong, Donald S ^a,b  

^a Southern California Permanente Medical Group   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; AGING; HUMAN; PSYCHOLOGICAL ASPECT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SCREENING TEST; SOCIAL SUPPORT; VISION TEST;

AGE FACTORS; HUMANS; INCIDENCE; LASER COAGULATION; MACULAR DEGENERATION; RISK FACTORS;

EID: 0034657438     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Brenner MH, Curbow B, Javitt JC, Legro MW, Sommer A. Vision change and quality of life in the elderly. Response to cataract surgery and treatment of other chronic ocular conditions. Arch Ophthalmol 1993;111:680-5.
2. Mangione CM, Phillips RS, Lawrence MG, Seddon JM, Orav EJ, Goldman L. Improved visual function and attenuation of declines in health-related quality of life after cataract extraction. Arch Ophthalmol 1994;112:1419-25.
3. Kahn HA, Moorehead HB. Statistics on blindness in the model reporting area, 1969-1970. Washington, D.C.: National Institutes of Health, 1973.
4. National Advisory Eye Council (U.S.) vision research: a national plan: 1994-1998. A report of the National Advisory Eye Council. Washington, D.C.: U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, 1993.
5. Williams RA, Brody BL, Thomas RG, Kaplan RM, Brown SI. The psychosocial impact of macular degeneration. Arch Ophthalmol 1998;116:514-20.
6. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 1993;13:89-102.
7. Davis C, Lovie-Kitchin J, Thompson B. Psychosocial adjustment to age-related macular degeneration. J Vis Impair Blind 1995;89:16-27.
8. Alexander MF, Maguire MG, Lietman TM, Snyder JR, Elman MJ, Fine SL. Assessment of visual function in patients with age-related macular degeneration and low visual acuity. Arch Ophthalmol 1988;106:1543-7.
9. Ganley JP, Roberts J. Eye conditions and related need for medical care. Vit Health Stat 11 1983:1-69.
10. Klein R, Rowland ML, Harris MI. Racial/ethnic differences in age-related maculopathy. Third National Health and Nutrition Examination Survey. Ophthalmology 1995;102:371-81 [Published erratum appears in Ophthalmology 1995;102:1126].
11. Bressler NM, Bressler SB, West SK, Fine SL, Taylor HR. The grading and prevalence of macular degeneration in Chesapeake Bay watermen. Arch Ophthalmol 1989;107:847-52.
12. Klein R, Klein BE, Union KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
13. Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1997;104:7-21.
14. Morse JH. Psychological aspects of low vision. In: Randal TJ, ed. Understanding low vision. New York: American Foundation for the Blind, 1983:43.
15. Jampol LM. Hypertension and visual outcome in the macular photocoagulation study [Editorial], Arch Ophthalmol 1991;109:789-90.
16. Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 1992;110:1701-8.
17. Petrukhin K, Koisti MJ, Bakall B, Li W, Xie G, Marknell T, et al. Identification of the gene responsible for Best macular dystrophy. Nat Genet 1998; 19:241-7.
18. Kohl S, Christ-Adler M, Apfelstedt-Sylla E, Kellner U, Eckstein A, Zrenner E, et al. RDS/peripherin gene mutations are frequent causes of central retinal dystrophies. J Med Genet 1997;34:620-6.
19. Allikmets R, Singh N, Sun H, Shroyer NF, Hutchinson A, Chidambaram A, et al. A photoreceptor cell-specific ATP-binding transporter gene (ABCR) is mutated in recessive Stargardt macular dystrophy. Nat Genet 1997;15:236-45
20. American Academy of Family Physicians. AAFP reference manual: selected policies on health issues, clinical policies, in-house (operational) policies. 1999-2000. Kansas City, Mo.: The Academy, 1999:213.
21. U.S. Preventive Services Task Force. Screening for visual impairment. In: Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. 2d ed. Baltimore: Williams & Wilkins, 1996:373-82.
22. American Academy of Ophthalmology Web Site. Retrieved March 16, 2000, from the World Wide Web: http://www.aao.org/public/pi/eye_health/ safety/ecm_care.html.
23. Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74.
24. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999;60:99-108.
25. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1109-14.
26. Laser photocoagulation for juxtafoveal choroidal neovascularization. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112:500-9.
27. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group Arch. Ophthalmol 1993;111:1200-9.
28. Freund KB, Yannuzzi LA, Sorenson JA. Age-related macular degeneration and choroidal neovascularization. Am J Ophthalmol 1993;115:786-91.
29. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
30. Seddon JM, Ajani UA, Sperduto RD, Miller R, Blair N, Burton TC, et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. Eye Disease Case-Control Study Group. JAMA 1994;272:1413-20 [Published erratum appears in JAMA 1995;273:622].
31. The effects of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35.
32. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334:1150-5.
33. Gaziano JM, Johnson EJ, Russell RM, Manson JE, Stampfer MJ, Ridker PM, et al. Discrimination in absorption or transport of beta-carotene isomers after oral supplementation with either all-trans-or 9-cis-beta-carotene. Am J Clin Nutr 1995;61:1248-52.
34. Sommerburg O, Keunen JE, Bird AC, van Kuijk FJ. Fruits and vegetables that are sources for lutein and zeaxanthin: the macular pigment in human eyes. Br. J Ophthalmol 1998;82:907-10.
35. Fong DS, Ross RD. The diabetes eye care source-book. Los Angeles: Lowell House, 1998:195-216.